Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiofrequency ablation with or without tislelizumab for hepatocellular carcinoma
ChiCTR2100047763Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tislelizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: 3-year recurrence-free survival rate. Started Jun 2021; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100047763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047763.